Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Impact of TP53 somatic mutations on prognosis in endometrial cancer: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Pooled it
- Trial
- Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UK.EClinicalMedicine · 2026Article
- Aberrant p53 fuels macrophage immunoregulatory polarization and refractory clinical outcome in urothelial carcinoma.Journal for immunotherapy of cancer · 2026Article
- Article
- Article
- Preclinical Combination Targeting VEGF and PI3K in a Rare, Aggressive Mixed Endometrial Carcinoma: An Applied Case Report.Cancer research communications · 2026Article
- Targeting mutant p53 in cancer: from mechanistic insights to therapeutic strategies.Cellular & molecular biology letters · 2026Review
- Comparison of clinical, pathological and genomic characteristics between Lynch and non-Lynch patients with MMRd endometrial carcinoma.BMC cancer · 2026Article
- Comparing multi-b-value diffusion models and ROI delineation strategies for prediction of p53 abnormality and microsatellite instability in endometrial cancer.BMC medical imaging · 2026Article
- EIF1AX Nucleolar Condensates Enhance Susceptibilities for the Management of Endometrial Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Review
- Integrin β3: structural functions, tumour microenvironment regulatory roles and targeted intervention strategies.Frontiers in immunology · 2026Review
- Genomic and immunological differences in endometrial cancer: a comparative study between young and old Asian patients.Frontiers in immunology · 2026Article
- A novel nomogram incorporating preoperative systemic inflammatory response index and clinicopathological parameters for predicting lymph node metastasis in endometrial cancer.Frontiers in oncology · 2026Article
- Preclinical validation of magnetic hyperthermia therapy for locally advanced oral cancer treatment.RSC advances · 2025Article
- Article
- Challenges in Fertility Preservation for p53abn Grade 2 Endometrioid Endometrial Cancer: A Case Report and Literature Review.Reproductive sciences (Thousand Oaks, Calif.) · 2025Review
- Review
- Nanocarrier drug delivery systems for gynecological cancer therapeutics.Journal of controlled release : official journal of the Controlled Release Society · 2025Review
Corrections and comments
- Commented on by
Authors and funding
16 authors at 12 institutions in 1 country.
Funding
Abstract
purposeThe status of p53 in a tumor can be inferred by next-generation sequencing (NGS) or by immunohistochemistry (IHC). We examined the association between p53 IHC and sequence and whether p53 IHC alone, or integrated with
methodsFrom GOG-86P, a randomized phase II study of chemotherapy combined with either bevacizumab or temsirolimus in advanced endometrial cancer, 213 cases had p53 protein expression data measured by IHC and
resultsIn the analysis of p53 IHC, the most striking treatment effect favoring bevacizumab was in cases where p53 was overexpressed (PFS hazard ratio [HR]: 0.46, 95% CI, 0.26 to 0.88; OS HR: 0.31, 95% CI, 0.16 to 0.62). On integrated analysis, patients with
conclusionIHC for p53 alone or when integrated with sequencing for
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.